公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2016 | Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial | Piccart-Gebhart M.; Holmes E.; Baselga J.; De Azambuja E.; Dueck A.C.; Viale G.; Zujewski J.A.; Goldhirsch A.; Armour A.; Pritchard K.I.; McCullough A.E.; Dolci S.; McFadden E.; Holmes A.P.; Tonghua L.; Eidtmann H.; Dinh P.; Di Cosimo S.; Harbeck N.; Tjulandin S.; Im Y.-H.; CHIUN-SHENG HUANG ; Diéras V.; Hillman D.W.; Wolff A.C.; Jackisch C.; Lang I.; Untch M.; Smith I.; Boyle F.; Xu B.; Gomez H.; Suter T.; Gelber R.D.; Perez E.A. | Journal of Clinical Oncology | 307 | 277 | |
2018 | Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308)) | Curigliano G.; Burstein H.J.; Winer E.P.; Gnant M.; Dubsky P.; Loibl S.; Colleoni M.; Regan M.M.; Piccart-Gebhart M.; Senn H.-J.; Th?rlimann B.; Andr? F.; Baselga J.; Bergh J.; Bonnefoi H.; Brucker S.Y.; Cardoso F.; Carey L.; Ciruelos E.; Cuzick J.; Denkert C.; Di Leo A.; Ejlertsen B.; Francis P.; Galimberti V.; Garber J.; Gulluoglu B.; Goodwin P.; Harbeck N.; Hayes D.F.; CHIUN-SHENG HUANG ; Huober J.; Khaled H.; Jassem J.; Jiang Z.; Karlsson P.; Morrow M.; Orecchia R.; Osborne K.C.; Pagani O.; Partridge A.H.; Pritchard K.; Ro J.; Rutgers E.J.T.; Sedlmayer F.; Semiglazov V.; Shao Z.; Smith I.; Toi M.; Tutt A.; Viale G.; Watanabe T.; Whelan T.J.; Xu B. | Annals of Oncology | 28 | 35 | |
2017 | De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 | Curigliano G.; Burstein H.J.; Winer E.P.; Gnant M.; Dubsky P.; Loibl S.; Colleoni M.; M. Regan M.; Piccart-Gebhart M.; Senn H.-J.; Th?rlimann B.; Andr? F.; Baselga J.; Bergh J.; Bonnefoi H.; Brucker S.Y.; Cardoso F.; Carey L.; Ciruelos E.; Cuzick J.; Denkert C.; Di Leo A.; Ejlertsen B.; Francis P.; Galimberti V.; Garber J.; Gulluoglu B.; Goodwin P.; Harbeck N.; F. Hayes D.; CHIUN-SHENG HUANG ; Huober J.; Hussein K.; Jassem J.; Jiang Z.; Karlsson P.; Morrow M.; Orecchia R.; Osborne K.C.; Pagani O.; Partridge A.H.; Pritchard K.; Ro J.; Rutgers E.J.T.; Sedlmayer F.; Semiglazov V.; Shao Z.; Smith I.; Toi M.; Tutt A.; Viale G.; Watanabe T.; Whelan T.J.; Xu B. | Annals of Oncology | 814 | 691 | |
2014 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response | De Azambuja E.; Holmes A.P.; Piccart-Gebhart M.; Holmes E.; Di Cosimo S.; Swaby R.F.; Untch M.; Jackisch C.; Lang I.; Smith I.; Boyle F.; Xu B.; Barrios C.H.; Perez E.A.; Azim H.A.; Kim S.-B.; Kuemmel S.; CHIUN-SHENG HUANG ; Vuylsteke P.; Hsieh R.-K.; Gorbunova V.; Eniu A.; Dreosti L.; Tavartkiladze N.; Gelber R.D.; Eidtmann H.; Baselga J. | The Lancet Oncology | 387 | 330 | |
2013 | Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: Analysis from the NeoALTTO trial | Azim H.A.; Agbor-Tarh D.; Bradbury I.; Dinh P.; Baselga J.; Di Cosimo S.; Greger Jr. J.G.; Smith I.; Jackisch C.; Kim S.-B.; Aktas B.; CHIUN-SHENG HUANG ; Vuylsteke P.; Hsieh R.K.; Dreosti L.; Eidtmann H.; Piccart M.; De Azambuja E. | Journal of Clinical Oncology | 48 | 47 | |
2018 | Reply to 'the St Gallen international expert consensus on the primary therapy of early breast cancer 2017: Te point of view of an international panel of experts in radiation oncology' by Kirova et al. | Dubsky P.; Curigliano G.; Burstein H.J.; Winer E.P.; Gnant M.; Loibl S.; Colleoni M.; Regan M.M.; Piccart-Gebhart M.; Senn H.-J.; Thrlimann B.; Andr? F.; Baselga J.; Bergh J.; Bonnefoi H.; Brucker S.Y.; Cardoso F.; Carey L.; Ciruelos E.; Cuzick J.; Denkert C.; Di Leo A.; Ejlertsen B.; Francis P.; Galimberti V.; Garber J.; Gulluoglu B.; Goodwin P.; Harbeck N.; Hayes D.F.; CHIUN-SHENG HUANG ; Huober J.; Khaled H.; Jassem J.; Jiang Z.; Karlsson P.; Morrow M.; Orecchia R.; Osborne K.C.; Pagani O.; Partridge A.H.; Pritchard K.; Ro J.; Rutgers E.J.T.; Sedlmayer F.; Semiglazov V.; Shao Z.; Smith I.; Toi M.; Tutt A.; Viale G.; Watanabe T.; Whelan T.J.; Xu B.; on behalf of the Panel Members of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 | Annals of Oncology | 2 | 3 | |
2005 | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Piccart-Gebhart M.J.; Procter M.; Leyland-Jones B.; Goldhirsch A.; Untch M.; Smith I.; Gianni L.; Baselga J.; Bell R.; Jackisch C.; Cameron D.; Dowsett M.; Barrios C.H.; Steger G.; CHIUN-SHENG HUANG ; Andersson M.; Inbar M.; Lichinitser M.; L?ng I.; Nitz U.; Iwata H.; Thomssen C.; Lohrisch C.; Suter T.M.; R?schoff J.; S?to T.; Greatorex V.; Ward C.; Straehle C.; McFadden E.; Dolci M.S.; Gelber R.D. | New England Journal of Medicine | 4386 | 3899 |